HLA-Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide after Busulfan-Containing Reduced-Intensity Conditioning

on behalf of the Japan Study Group for Cell Therapy and Transplantation

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Allogeneic hematopoietic stem cell transplantation (allo-SCT) using post-transplant cyclophosphamide (PTCy) is increasingly performed. We conducted a multicenter phase II study to evaluate the safety and efficacy of PTCy-based HLA-haploidentical peripheral blood stem cell transplantation (PTCy-haploPBSCT) after busulfan-containing reduced-intensity conditioning. Thirty-one patients were enrolled; 61% patients were not in remission and 42% patients had a history of prior allo-SCT. Neutrophil engraftment was achieved in 87% patients with a median of 19 days. The cumulative incidence of grades II to IV and III to IV acute graft-versus-host disease (GVHD) and chronic GVHD at 1 year were 23%, 3%, and 15%, respectively. No patients developed severe chronic GVHD. Day 100 nonrelapse mortality (NRM) rate was 19.4%. Overall survival, relapse, and disease-free survival rates were 45%, 45%, and 34%, respectively, at 1 year. Subgroup analysis showed that patients who had a history of prior allo-SCT had lower engraftment, higher NRM, and lower overall survival than those not receiving a prior allo-SCT. Our results suggest that PTCy-haploPBSCT after busulfan-containing reduced-intensity conditioning achieved low incidences of acute and chronic GVHD and NRM and stable donor engraftment and low NRM, particularly in patients without a history of prior allo-SCT.

Original languageEnglish
Pages (from-to)1646-1652
Number of pages7
JournalBiology of Blood and Marrow Transplantation
Volume21
Issue number9
DOIs
Publication statusPublished - Sep 1 2015

Fingerprint

Peripheral Blood Stem Cell Transplantation
Busulfan
Cyclophosphamide
Hematopoietic Stem Cell Transplantation
Transplants
Graft vs Host Disease
Mortality
Survival
Incidence
Disease-Free Survival
Neutrophils
Survival Rate
Tissue Donors
Safety
Recurrence

All Science Journal Classification (ASJC) codes

  • Hematology
  • Transplantation

Cite this

HLA-Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide after Busulfan-Containing Reduced-Intensity Conditioning. / on behalf of the Japan Study Group for Cell Therapy and Transplantation.

In: Biology of Blood and Marrow Transplantation, Vol. 21, No. 9, 01.09.2015, p. 1646-1652.

Research output: Contribution to journalArticle

@article{7b3e26d7d2db4fde9f545c5fb837ec20,
title = "HLA-Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide after Busulfan-Containing Reduced-Intensity Conditioning",
abstract = "Allogeneic hematopoietic stem cell transplantation (allo-SCT) using post-transplant cyclophosphamide (PTCy) is increasingly performed. We conducted a multicenter phase II study to evaluate the safety and efficacy of PTCy-based HLA-haploidentical peripheral blood stem cell transplantation (PTCy-haploPBSCT) after busulfan-containing reduced-intensity conditioning. Thirty-one patients were enrolled; 61{\%} patients were not in remission and 42{\%} patients had a history of prior allo-SCT. Neutrophil engraftment was achieved in 87{\%} patients with a median of 19 days. The cumulative incidence of grades II to IV and III to IV acute graft-versus-host disease (GVHD) and chronic GVHD at 1 year were 23{\%}, 3{\%}, and 15{\%}, respectively. No patients developed severe chronic GVHD. Day 100 nonrelapse mortality (NRM) rate was 19.4{\%}. Overall survival, relapse, and disease-free survival rates were 45{\%}, 45{\%}, and 34{\%}, respectively, at 1 year. Subgroup analysis showed that patients who had a history of prior allo-SCT had lower engraftment, higher NRM, and lower overall survival than those not receiving a prior allo-SCT. Our results suggest that PTCy-haploPBSCT after busulfan-containing reduced-intensity conditioning achieved low incidences of acute and chronic GVHD and NRM and stable donor engraftment and low NRM, particularly in patients without a history of prior allo-SCT.",
author = "{on behalf of the Japan Study Group for Cell Therapy and Transplantation} and Junichi Sugita and Naomi Kawashima and Tomoaki Fujisaki and Kazuhiko Kakihana and Shuichi Ota and Keitaro Matsuo and Toshihiro Miyamoto and Koichi Akashi and Shuichi Taniguchi and Mine Harada and Takanori Teshima",
year = "2015",
month = "9",
day = "1",
doi = "10.1016/j.bbmt.2015.06.008",
language = "English",
volume = "21",
pages = "1646--1652",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "9",

}

TY - JOUR

T1 - HLA-Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide after Busulfan-Containing Reduced-Intensity Conditioning

AU - on behalf of the Japan Study Group for Cell Therapy and Transplantation

AU - Sugita, Junichi

AU - Kawashima, Naomi

AU - Fujisaki, Tomoaki

AU - Kakihana, Kazuhiko

AU - Ota, Shuichi

AU - Matsuo, Keitaro

AU - Miyamoto, Toshihiro

AU - Akashi, Koichi

AU - Taniguchi, Shuichi

AU - Harada, Mine

AU - Teshima, Takanori

PY - 2015/9/1

Y1 - 2015/9/1

N2 - Allogeneic hematopoietic stem cell transplantation (allo-SCT) using post-transplant cyclophosphamide (PTCy) is increasingly performed. We conducted a multicenter phase II study to evaluate the safety and efficacy of PTCy-based HLA-haploidentical peripheral blood stem cell transplantation (PTCy-haploPBSCT) after busulfan-containing reduced-intensity conditioning. Thirty-one patients were enrolled; 61% patients were not in remission and 42% patients had a history of prior allo-SCT. Neutrophil engraftment was achieved in 87% patients with a median of 19 days. The cumulative incidence of grades II to IV and III to IV acute graft-versus-host disease (GVHD) and chronic GVHD at 1 year were 23%, 3%, and 15%, respectively. No patients developed severe chronic GVHD. Day 100 nonrelapse mortality (NRM) rate was 19.4%. Overall survival, relapse, and disease-free survival rates were 45%, 45%, and 34%, respectively, at 1 year. Subgroup analysis showed that patients who had a history of prior allo-SCT had lower engraftment, higher NRM, and lower overall survival than those not receiving a prior allo-SCT. Our results suggest that PTCy-haploPBSCT after busulfan-containing reduced-intensity conditioning achieved low incidences of acute and chronic GVHD and NRM and stable donor engraftment and low NRM, particularly in patients without a history of prior allo-SCT.

AB - Allogeneic hematopoietic stem cell transplantation (allo-SCT) using post-transplant cyclophosphamide (PTCy) is increasingly performed. We conducted a multicenter phase II study to evaluate the safety and efficacy of PTCy-based HLA-haploidentical peripheral blood stem cell transplantation (PTCy-haploPBSCT) after busulfan-containing reduced-intensity conditioning. Thirty-one patients were enrolled; 61% patients were not in remission and 42% patients had a history of prior allo-SCT. Neutrophil engraftment was achieved in 87% patients with a median of 19 days. The cumulative incidence of grades II to IV and III to IV acute graft-versus-host disease (GVHD) and chronic GVHD at 1 year were 23%, 3%, and 15%, respectively. No patients developed severe chronic GVHD. Day 100 nonrelapse mortality (NRM) rate was 19.4%. Overall survival, relapse, and disease-free survival rates were 45%, 45%, and 34%, respectively, at 1 year. Subgroup analysis showed that patients who had a history of prior allo-SCT had lower engraftment, higher NRM, and lower overall survival than those not receiving a prior allo-SCT. Our results suggest that PTCy-haploPBSCT after busulfan-containing reduced-intensity conditioning achieved low incidences of acute and chronic GVHD and NRM and stable donor engraftment and low NRM, particularly in patients without a history of prior allo-SCT.

UR - http://www.scopus.com/inward/record.url?scp=84938909900&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938909900&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2015.06.008

DO - 10.1016/j.bbmt.2015.06.008

M3 - Article

C2 - 26093044

AN - SCOPUS:84938909900

VL - 21

SP - 1646

EP - 1652

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 9

ER -